Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonacog beta pegol in previously untreated pediatric hemophilia B patients
NCT02141074Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2014
- Primary completion
- Oct 2022
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
A Phase 3 trial of nonacog beta pegol in hemophilia B (HB), sponsored by Novo Nordisk. Started Jul 2014; status: completed.
02
Drugs
nonacog beta pegol
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT02141074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141074.